Ipca Laboratories Q1 FY27 beat lifts growth and margin guidance

Investment View and Valuation

Prabhudas Lilladher retained its BUY rating on Ipca Laboratories following the company’s August 16, 2026 Q1FY27 result update and raised its target price to Rs 2,000 per share from Rs 1,800. The positive view reflects a strong Q1FY27 earnings beat, higher FY27 growth and margin guidance, continued strength in domestic formulations and branded generics, recovery in APIs, and improving profitability excluding Unichem.

PL values Ipca Laboratories at 30 times FY28E earnings per share. At the report CMP of Rs 1,734, the stock traded at 16 times FY28E EV/EBITDA and 25 times FY28E P/E after adjusting for the Unichem stake.

Q1FY27 Financial Performance

Ipca Laboratories reported Q1FY27 consolidated revenue of Rs 27,881 million, up 21 per cent year on year and 10 per cent above PL’s estimate of Rs 25,275 million. Revenue excluding Unichem also grew 21 per cent year on year.

Profitability was materially ahead of PL’s expectations. EBITDA was Rs 6,378 million, up 50 per cent year on year and 27 per cent above PL’s estimate of Rs 5,027 million. EBITDA margin expanded 450 basis points year on year to 22.9 per cent, supported by export-formulation growth and gross-margin improvement. Consolidated gross margin improved 135 basis points year on year to approximately 71 per cent.

Other expenses included a Rs 316 million foreign-exchange gain. After adjusting for this gain, EBITDA was Rs 6,400 million and adjusted profit after tax was Rs 3,800 million, or approximately Rs 15 per share. Unichem’s margin was 11 per cent, improving 680 basis points year on year. Excluding Unichem, Ipca delivered a gross margin of 76.4 per cent and an operating margin of 26.4 per cent.

FY27 Guidance and Earnings Estimates

Management raised FY27 revenue-growth guidance to 14-16 per cent from 12-13 per cent and operating-margin guidance to 23 per cent from 22 per cent. PL increased its FY27E and FY28E EPS estimates by 6.8 per cent and 3.9 per cent, respectively, to Rs 58.0 and Rs 66.7.

PL expects FY28E domestic formulations, domestic APIs, export formulations and export APIs to reach Rs 47,668 million, Rs 4,222 million, Rs 27,301 million and Rs 13,473 million, respectively.

Business Outlook and Capacity Expansion

Management commentary indicated that chronic therapies grew 17.2 per cent in Q1FY27 compared with 8.9 per cent for acute therapies. Growth was led by urology, CNS, cardiovascular and anti-diabetic therapies, dermatology and ophthalmology. Anti-malarial revenue declined 24 per cent and represented approximately 1 per cent of the domestic business.

• Ipca expects US-business growth potential of approximately 15-17 per cent, supported by launches and portfolio optimisation.
• The combined Ipca and Unichem portfolio plans approximately 7-8 US launches and 4-5 new filings annually.
• Europe and UK generic exports grew 70 per cent year on year.
• Institutional-business growth is expected to normalise to single digits, with annual business estimated at Rs 2,500-3,000 million.
• API capacity utilisation at Ratlam is nearing limits, while new API and intermediate capacity is being developed at Dewas and Wardha.
• Management guided FY27E capex of Rs 7,000-8,000 million for formulations, biotech and API/intermediate expansion.

Risks and Constraints

• Freight costs have risen sharply across South America, the US and Europe because of container shortages.
• Institutional-business growth is expected to normalise.
• Existing API capacity limitations could constrain growth.